Bioxytran Inc Financials
This page shows Bioxytran Inc (BIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Bioxytran operates as a cash-funded development company, with financing inflows repeatedly covering operating burn while liabilities remain larger than assets.
FY2025 looked healthier on cash than on earnings: a$1.05M financing inflow lifted cash to$510K from$5K in FY2024 even though operating loss was-$1.84M and operating cash flow was only-$526K . That gap means the immediate constraint is access to outside capital, because the balance sheet still carries$3.25M of liabilities against just$659K of assets.
Small investing outflows — just
Liquidity improved sharply, with the current ratio rising to 0.158x in FY2025 from 0.0027x in FY2024, but it remains far below 1.0x and sits beside
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Bioxytran Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bioxytran Inc has a moderate D/E ratio of -1.25. This balance of debt and equity financing earns a leverage score of 53/100.
Bioxytran Inc's current ratio of 0.16 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Bioxytran Inc passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Bioxytran Inc generates $0.25 in operating cash flow (-$526K OCF vs -$2.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Bioxytran Inc earns $-13.7 in operating income for every $1 of interest expense (-$1.8M vs $134K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Bioxytran Inc reported -$2.1M in net income in fiscal year 2025.
Bioxytran Inc earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Bioxytran Inc held $510K in cash against $0 in long-term debt as of fiscal year 2025.
Bioxytran Inc had 108M shares outstanding in fiscal year 2025. This represents an increase of 22.7% from the prior year.
Margins & Returns
Capital Allocation
Bioxytran Inc invested $454K in research and development in fiscal year 2025. This represents an increase of 304.1% from the prior year.
BIXT Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $225K | N/A | N/A | $103K-70.7% | $350K | N/A | $51K | N/A |
| SG&A Expenses | $214K | N/A | $159K+59.9% | $100K-30.8% | $144K | N/A | $158K-64.7% | $448K |
| Operating Income | -$1.9M | N/A | -$496K-121.4% | -$224K+56.5% | -$515K | N/A | -$346K+43.2% | -$609K |
| Interest Expense | $36K | N/A | $37K+21.3% | $30K-3.4% | $31K | N/A | $18K-9.6% | $20K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.1M | N/A | -$283K-897.8% | $35K | N/A | N/A | -$392K | N/A |
| EPS (Diluted) | $-0.02 | N/A | $0.00 | $0.00+100.0% | $-0.02 | N/A | $0.00 | $0.00 |
BIXT Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $615K-6.6% | $659K+321.4% | $156K+6.0% | $148K+8.4% | $136K-1.9% | $139K-12.8% | $159K+23.7% | $129K |
| Current Assets | $463K-9.8% | $513K+3441.4% | $14K+361.2% | $3K-27.7% | $4K-15.6% | $5K-85.1% | $35K+156.4% | $14K |
| Cash & Equivalents | $463K-9.2% | $510K+3416.9% | $14K+361.2% | $3K-27.7% | $4K-15.6% | $5K-85.1% | $35K+156.4% | $14K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.0M+54.2% | $3.2M+6.2% | $3.1M+10.0% | $2.8M-2.2% | $2.8M+47.3% | $1.9M+55.2% | $1.2M+1.2% | $1.2M |
| Current Liabilities | $5.0M+54.2% | $3.2M+6.2% | $3.1M+10.0% | $2.8M-2.2% | $2.8M+47.3% | $1.9M+55.2% | $1.2M+1.2% | $1.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$4.4M-69.6% | -$2.6M+10.8% | -$2.9M-10.2% | -$2.6M+2.7% | -$2.7M-51.1% | -$1.8M-65.2% | -$1.1M+1.4% | -$1.1M |
| Retained Earnings | -$23.1M-9.8% | -$21.0M-2.5% | -$20.5M-1.4% | -$20.2M+0.2% | -$20.3M-7.2% | -$18.9M-3.4% | -$18.3M-7.9% | -$17.0M |
BIXT Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$239K-0.7% | -$237K-471.4% | -$41K+48.6% | -$81K+51.8% | -$167K-30.8% | -$128K-74.0% | -$74K-4.7% | -$70K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$9K-47.9% | -$6K-272.8% | -$2K+89.0% | -$15K-100980.0% | -$15+99.9% | -$12K-11.6% | -$11K-1661.5% | $693 |
| Financing Cash Flow | $201K-72.8% | $739K+1255.2% | $55K-42.4% | $95K-43.2% | $167K+50.7% | $110K+4.7% | $106K+44.4% | $73K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BIXT Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -336.3% | N/A | -180.9%-204.9pp | 24.0% | N/A | N/A | -246.8% | N/A |
| Current Ratio | 0.09-0.1 | 0.16+0.2 | 0.000.0 | 0.000.0 | 0.000.0 | 0.00-0.0 | 0.03+0.0 | 0.01 |
| Debt-to-Equity | -1.14+0.1 | -1.25-0.2 | -1.050.0 | -1.060.0 | -1.05+0.0 | -1.08+0.1 | -1.15-0.0 | -1.12 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$2.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.16), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Bioxytran Inc profitable?
No, Bioxytran Inc (BIXT) reported a net income of -$2.1M in fiscal year 2025.
What is Bioxytran Inc's operating cash flow?
Bioxytran Inc (BIXT) generated -$526K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bioxytran Inc's total assets?
Bioxytran Inc (BIXT) had $659K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Bioxytran Inc spend on research and development?
Bioxytran Inc (BIXT) invested $454K in research and development during fiscal year 2025.
What is Bioxytran Inc's current ratio?
Bioxytran Inc (BIXT) had a current ratio of 0.16 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Bioxytran Inc's debt-to-equity ratio?
Bioxytran Inc (BIXT) had a debt-to-equity ratio of -1.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bioxytran Inc's return on assets (ROA)?
Bioxytran Inc (BIXT) had a return on assets of -322.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bioxytran Inc's cash runway?
Based on fiscal year 2025 data, Bioxytran Inc (BIXT) had $510K in cash against an annual operating cash burn of $526K. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Bioxytran Inc's debt-to-equity ratio negative or unusual?
Bioxytran Inc (BIXT) has negative shareholder equity of -$2.6M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Bioxytran Inc's Piotroski F-Score?
Bioxytran Inc (BIXT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioxytran Inc's earnings high quality?
Bioxytran Inc (BIXT) has an earnings quality ratio of 0.25x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bioxytran Inc cover its interest payments?
Bioxytran Inc (BIXT) has an interest coverage ratio of -13.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioxytran Inc?
Bioxytran Inc (BIXT) scores 9 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.